Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) Operating Margin (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Operating Margin for 6 consecutive years, with 10535.66% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Margin fell 567556.0% year-over-year to 10535.66%, compared with a TTM value of 13034.81% through Sep 2025, up 400160.0%, and an annual FY2024 reading of 454.07%, up 1000902.0% over the prior year.
  • Operating Margin was 10535.66% for Q3 2025 at Barinthus Biotherapeutics, up from 2332400.0% in the prior quarter.
  • Across five years, Operating Margin topped out at 1666800.0% in Q4 2021 and bottomed at 2332400.0% in Q2 2025.
  • Average Operating Margin over 5 years is 32967.6%, with a median of 5689.55% recorded in 2025.
  • The sharpest move saw Operating Margin crashed -166718862bps in 2022, then soared 28593147bps in 2023.
  • Year by year, Operating Margin stood at 1666800.0% in 2021, then crashed by -100bps to 388.62% in 2022, then surged by 73577bps to 285542.86% in 2023, then crashed by -105bps to 13598.84% in 2024, then grew by 23bps to 10535.66% in 2025.
  • Business Quant data shows Operating Margin for BRNS at 10535.66% in Q3 2025, 2332400.0% in Q2 2025, and 6518.99% in Q1 2025.